Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Fibroblast-derived dermal matrix drives development of aggressive cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa.
[dystrophic epidermolysis bullosa]
Patients
with
the
genetic
skin
blistering
disease
recessive
dystrophic
epidermolysis
bullosa
(
RDEB
)
develop
aggressive
cutaneous
squamous
cell
carcinoma
(
cSCC
)
.
Metastasis
leading
to
mortality
is
greater
in
RDEB
than
in
other
patient
groups
with
cSCC
.
Here
we
investigate
the
dermal
component
in
RDEB
using
mRNA
expression
profiling
to
compare
cultured
fibroblasts
isolated
from
individuals
without
cSCC
and
directly
from
tumor
matrix
in
RDEB
and
non-
RDEB
samples
.
Although
gene
expression
of
RDEB
normal
skin
fibroblasts
resembled
that
of
cancer
-associated
fibroblasts
,
RDEB
cancer
-associated
fibroblasts
exhibited
a
distinct
and
divergent
gene
expression
profile
,
with
a
large
proportion
of
the
differentially
expressed
genes
involved
in
matrix
and
cell
adhesion
.
RDEB
cancer
-associated
fibroblasts
conferred
increased
adhesion
and
invasion
to
tumor
and
nontumor
keratinocytes
.
Reduction
of
COL
7
A
1
,
the
defective
gene
in
RDEB
,
in
normal
dermal
fibroblasts
led
to
increased
type
XII
collagen
,
thrombospondin-
1
,
and
Wnt-
5
A
,
while
reexpression
of
wild
type
COL
7
A
1
in
RDEB
fibroblasts
decreased
type
XII
collagen
,
thrombospondin-
1
,
and
Wnt-
5
A
expression
,
reduced
tumor
cell
invasion
in
organotypic
culture
,
and
restricted
tumor
growth
in
vivo
.
Overall
,
our
findings
show
that
matrix
composition
in
patients
with
RDEB
is
a
permissive
environment
for
tumor
development
,
and
type
VII
collagen
directly
regulates
the
composition
of
matrix
proteins
secreted
by
dermal
and
cancer
-associated
fibroblasts
.
Diseases
Validation
Diseases presenting
"tumor development"
symptom
congenital adrenal hyperplasia
dystrophic epidermolysis bullosa
esophageal squamous cell carcinoma
familial hypocalciuric hypercalcemia
liposarcoma
lymphangioleiomyomatosis
oral submucous fibrosis
primary effusion lymphoma
severe combined immunodeficiency
wolf-hirschhorn syndrome
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom